Brief: Circio Holding's Partner IOVaxis Therapeutics Exercises Option For Exclusive License

Circio Holding ASA

19/03/2024 11:46

March 19 (Reuters) - Circio Holding ASA  CRNA.OL :
    * PARTNER IOVAXIS THERAPEUTICS HAS EXERCISED OPTION FOR AN
EXCLUSIVE LICENSE TO MUTANT RAS CANCER VACCINE TG01 IN CHINA
    * UNDER LICENSE AGREEMENT BETWEEN PARTIES, CIRCIO IS
ENTITLED TO
RECEIVE A MILESTONE PAYMENT OF USD 3 MILLION
    * TOTAL DEAL INCLUDES UP TO USD 10M IN CLINICAL DEVELOPMENT
MILESTONES, ROYALTIES AND COMMERCIAL MILESTONES ON FUTURE SALES

Source text for Eikon:  ID:nObiZDcC7a 
Further company coverage:  CRNA.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))